Zoetis Reports Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil slips as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Zoetis Inc. (ZTS) PT Raised to $65 at Guggenheim Following 4Q Report
February 16, 2017 11:59 AM ESTGuggenheim raised its price target on Zoetis Inc. (NYSE: ZTS) to $65.00 (from $60.00) while maintaining a Buy rating. ZTS reported 4Q16 EPS of $0.47, $0.02 higher than consensus. ZTS decreased its '17 EPS guidance, slightly, by $0.02 from $2.28-$2.38 to $2.26-$2.36, or $2.31 at the... More
Zoetis (ZTS) Tops Q4 EPS by 2c; Guides In-Line
February 16, 2017 7:01 AM ESTZoetis (NYSE: ZTS) reported Q4 EPS of $0.47, $0.02 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.27 billion.
GUIDANCE:
Zoetis sees FY2017 EPS of $2.26-$2.36, versus the consensus of $2.33. Zoetis sees... More
